In a decisive move against the growing threat of drug abuse in India, the Enforcement Directorate (ED) launched an extensive investigation into the illegal sale of addiction treatment medicines. The agency conducted multiple high-profile raids at rehab centres in Punjab and a pharmaceutical company in Maharashtra, exposing a vast network of misuse, fraud, and medical malpractice.
ED raids rehab centres in Punjab and Maharashtra, at the heart of this case is Dr. Amit Bansal, a de-addiction specialist whose chain of 22 rehabilitation clinics across Punjab is now under investigation. These centres were legally authorised to dispense Buprenorphine/Naloxone (BNX)—a combination drug used in opioid addiction treatment. However, the ED found alarming evidence that these medications were being diverted into black markets under the guise of patient treatment.
What began as a localised probe has now grown into a significant illegal drug sale case in India, with financial links traced from Punjab to Maharashtra. During simultaneous searches, the ED also raided the premises of Rusan Pharma Ltd, a Mumbai-based pharmaceutical company that manufactures BNX. Authorities suspect the company supplied excessive amounts of the drug to centres that lacked the patient numbers to justify such high quantities, raising red flags about inventory manipulation and regulatory failure.
What the ED Found
According to ED officials, the targeted centres were licensed to dispense Buprenorphine and Naloxone (BNX)—a critical medication used to treat opioid addiction. However, investigations suggest that these medications were being diverted in large quantities for sale on the black market.
The ED suspects that Dr. Amit Bansal and his associates were hoarding BNX tablets far beyond the number required for legitimate treatment. As per preliminary reports, more than 100,000 pills may have been illegally diverted.
An official from the ED, speaking on the condition of anonymity, said:
“The network was sophisticated. It involved falsifying inspection reports, misreporting stock usage, and laundering proceeds through a chain of shell entities. We have seized documents, digital records, and are analysing financial trails.”
This action is being seen as a critical escalation in the ED raids on rehab centres in Punjab suspected of involvement in illegal drug distribution. The investigation is currently focused on tracing the entire supply chain—from manufacturing to final sale.
Maharashtra Link: Pharma Firm Under Scanner
The agency also raided the Mumbai-based Rusan Pharma Ltd, which manufactures BNX. The company has been accused of supplying BNX tablets in volumes exceeding legal limits to rehab clinics that didn’t require them.
Investigators believe that the excess medicine was then pushed into illegal markets, both domestically and possibly abroad. The ED is verifying the company’s export and supply chain records for discrepancies.
A source familiar with the case stated:
Rusan Pharma is being investigated for its role in enabling the over-supply of BNX. This could not have occurred without lapses—or complicity—in their internal compliance mechanisms.”
Fallout in Punjab: Patients, Families in Limbo
The immediate impact of the raids has been felt in Punjab, where several of the de-addiction centres have been shut down or temporarily suspended pending the outcome of the investigation. This has left hundreds of patients in a state of uncertainty.
For families battling addiction, these centres were a lifeline. Now, many are unsure about where to continue treatment. One affected family member in Ludhiana said:
“We trusted the clinic with our son’s recovery. Now, we’re being told the medicines were part of an illegal racket. What are we supposed to do now?”
Government and Police Response
Punjab’s Health Department confirmed that it had suspended the licenses of all 22 centres linked to Dr. Bansal earlier in the year, after an FIR was filed in January by the Punjab Vigilance Bureau. The ED’s recent raids build upon that earlier action.
A senior official from the Punjab government stated:
“We had initiated disciplinary action months ago. Now with the ED involved, the financial aspect of the racket is being exposed.”
The Punjab Police, meanwhile, have continued their state-wide anti-drug initiative, “Yudh Nashian De Virudh”, under which more than 15,000 drug peddlers have been arrested since March 2024. The operation has also led to the seizure of over 600 kilograms of heroin and cash worth ₹10.8 crore.
ED’s National Crackdown Strategy
The latest action reflects a larger trend. Over the past two years, the ED has increasingly focused on drug-linked money laundering cases, especially those involving white-collar criminals in the healthcare and pharmaceutical industries.
By following the money trail rather than just the narcotics, the ED is taking a financial approach to drug enforcement—one that aims to dismantle the infrastructure of drug operations, not just the end dealers.
This shift in focus is evident in the growing number of PMLA (Prevention of Money Laundering Act) cases filed against medical institutions and pharmaceutical companies.
Drug Abuse and Climate Crisis Collide in Punjab
Adding to the state’s woes is a severe heatwave that has gripped large parts of Punjab over the past two weeks. With temperatures soaring past 46°C in Bathinda and Amritsar, public health services are under intense pressure.
Meteorologist Mahesh Palawat from Skymet Weather explained:
“The northwestern region is witnessing extreme heat due to stagnant hot air masses and the absence of pre-monsoon showers. This has pushed daily highs 4–5 degrees above normal.”
In such weather, addiction and dehydration can be a fatal mix. Health experts worry that patients dependent on opioids or recovering from substance abuse are especially vulnerable. The Indian Meteorological Department (IMD) has issued a “Red Alert” in Punjab, warning of prolonged heat exposure and urging the public to stay indoors between 12 PM and 4 PM.
Public Reaction and Expert Commentary
The raids have generated mixed reactions. While many have praised the ED’s action, some civil society groups are urging caution, especially in dealing with patients who may not have been aware of the clinic’s alleged malpractice.
Social worker Simran Bhullar, who runs a non-profit for addiction recovery in Patiala, said:
“We welcome strict action against corruption. But authorities must ensure continuity of care for patients, or else we risk pushing them back into addiction or even worse.”
Healthcare professionals are now calling for a complete audit of all licensed rehab centres in India, especially those dealing with controlled substances.
Lessons Learned and The Road Ahead
This entire episode has highlighted several systemic issues:
- Regulatory Gaps: The oversight mechanisms for rehab centres and pharmaceutical distribution need strengthening. Inspections must be regular and independent.
- Supply Chain Vulnerabilities: Lax tracking of addiction treatment drugs creates opportunities for diversion into illegal markets.
- Need for Public Awareness: Families must be informed about the credentials and legitimacy of the centres they approach.
The ED has assured that this is only the first phase of its ongoing operation. More arrests and seizures are expected in the coming weeks.
Final Thoughts
The recent ED action against rehab centres in Punjab and Maharashtra is not just a story of legal enforcement—it is a wake-up call for the country’s healthcare and law enforcement systems. By uncovering a widespread misuse of prescription drugs under the protection of legal de-addiction clinics, the ED has opened a new chapter in India’s fight against narcotics: one that highlights how white-collar corruption can undermine public health and trust.
The case underscores a pressing reality—drug trafficking in India is no longer limited to illegal imports or smuggling across borders. It has infiltrated licensed institutions, which are operated by professionals expected to uphold the highest ethical standards. When rehab centres become hubs for ED crackdown on illegal drug sales, the consequences are severe, not only for patients but also for the integrity of the nation’s healthcare system.
